Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2347-2355

  Gross, E ^a   Meul, C ^a   Raab, S ^a   Propping, C ^a   Avril, S ^b   Aubele, M ^c   Gkazepis, A ^a   Schuster, T ^d   Grebenchtchikov, N ^e   Schmitt, M ^a   Kiechle, M ^a   Meijer, J ^f   Vijzelaar, R ^g   Meindl, A ^a   Van Kuilenburg, A B P ^f  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g MRC HOLLAND   (Netherlands)

Author keywords

BRCA1; copy number changes; DPYD; fragile sites; triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CONCENTRATION (PARAMETERS); COPY NUMBER VARIATION; DISEASE SEVERITY; DNA REPAIR; FEMALE; GENE DELETION; GENE DUPLICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84887024612     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.621     Document Type: Article

References (49)

1. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med 9(5): E1001216.
2. Arlt MF, Durkin SG, Ragland RL, Glover TW (2006) Common fragile sites as targets for chromosome rearrangements. DNA Repair (Amst) 5(9-10): 1126-1135.
3. Arlt MF, Xu B, Durkin SG, Casper AM, Kastan MB, Glover TW (2004) BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Mol Cell Biol 24(15): 6701-6709.
4. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM (2007) PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-Term survival in breast carcinomas. Br J Cancer 96(5): 801-807.
5. Chacon RD, Costanzo MV (2010) Triple-negative breast cancer. Breast Cancer Res 12(Suppl 2): S3.
6. Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA (2010) Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, nodenegative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28(18): 2966-2973.
7. Dent R, TrudeauM, PritchardKI, HannaWM, Kahn HK, SawkaCA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1): 4429-4434.
8. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long-Term follow up. Histopathology 19: 403-410.
9. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G (1995) Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13(7): 1663-1670.
10. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB (2005) Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11(24 Pt 1): 8699-8705.
11. Fost C, Duwe F, Hellriegel M, Schweyer S, Emons G, Grundker C (2011) Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 25(5): 1481-1487.
12. Gerlach J, Löffler M, Schäfer MK (2011) Gene expression of enzymes required for the de novo synthesis and degradation of pyrimidines in rat peripheral tissues and brain. Nucleosides Nucleotides Nucleic Acids 30(12): 1147-1154.
13. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer - current status and future directions. Ann Oncol 20(12): 1913-1927.
14. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3): 725-731.
15. Ho DH, Townsend L, Luna MA, Bodey GP (1986) Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-luorouracil as a substrate. Anticancer Res 6(4): 781-784.
16. Holstege A, Pausch J, Gerok W (1986) Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys. Cancer Res 46(11): 5576-5581.
17. Hömig-Hölzel C, Savola S (2012) Multiplex ligation-dependent probe amplification(MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol 21(4): 189-206.
18. Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y, Morishita Y (2002) Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 86(2): 222-225.
19. Hormozian F, Schmitt JG, Sagulenko E, Schwab M, Savelyeva L (2007) FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD). Cancer Lett 246(1-2): 82-91.
20. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-Type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54(10): 2527-2530.
21. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y (2005) Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14(5): 1223-1230.
22. Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: Current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20(1): 40-46.
23. Kobunai T, Ooyama A, Sasaki S, Wierzba K, Takechi T, Fukushima M, Watanabe T, Nagawa H (2007) Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts. Eur J Cancer 43(4): 791-798.
24. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-Term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8): 1275-1281.
25. Linn SC, Van 't Veer LJ (2009) Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. Eur J Cancer 45(Suppl 1): 11-26.
26. Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53(22): 5433-5438.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2): 229-235.
28. Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ (2011) Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res 17(16): 5432-5442.
29. Pare L, Paez D, Salazar J, Del RE, Tizzano E, Marcuello E, Baiget M (2010) Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br J Clin Pharmacol 70(2): 268-272.
30. Punsawad C, Maneerat Y, Chaisri U, Nantavisai K, Viriyavejakul P (2013) Nuclear factor kappa B modulates apoptosis in the brain endothelial cells and intravascular leukocytes of fatal cerebral malaria. Malar J 12: 260.
31. Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378(9805): 1812-1823.
32. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: A critical review. Histopathology 52(1): 108-118.
33. Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC (2010) DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 123(1): 189-196.
34. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6(4): 1322-1327.
35. Saville DJ. Multiple comparison procedures: The practical solution (1990) Am Statist 44: 174-180.
36. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12): E57.
37. Schwartz M, Zlotorynski E, Kerem B (2006) The molecular basis of common and rare fragile sites. Cancer Lett 232(1): 13-26.
38. Shiotani T, Hashimoto Y, Fujita J, Yamauchi N, Yamaji Y, Futami H, Bungo M, Nakamura H, Tanaka T, Irino S (1989a) Reversal of enzymic phenotype of thymidine metabolism in induced differentiation of U-937 cells. Cancer Res 49(23): 6758-6763.
39. Shiotani T, Hashimoto Y, Tanaka T, Irino S (1989b) Behavior of activities of thymidine metabolizing enzymes in human leukemia-lymphoma cells. Cancer Res 49(5): 1090-1094.
40. Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z (2009) Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-Treated patients with high-grade toxicity. Cancer Chemother Pharmacol 64(3): 615-618.
41. Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43): 5846-5853.
42. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14): 2126-2132.
43. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376(9737): 235-244.
44. van Kuilenburg AB, Meijer J, Mul AN, Hennekam RC, Hoovers JM, de Die-Smulders CE, Weber P, Mori AC, Bierau J, Fowler B, Macke K, Sass JO, Meinsma R, Hennermann JB, Miny P, Zoetekouw L, Vijzelaar R, Nicolai J, Ylstra B, Rubio-Gozalbo ME (2009) Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3). Hum Genet 125(5-6): 581-590.
45. van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC, Klumpen HJ, Maring JG, Derleyn VA, Maartense E, Milano G, Vijzelaar R, Gross E (2010) Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 128(5): 529-538.
46. Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X (2011) Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol 29(2): 547-553.
47. Warnecke-Eberz U, Metzger R, Bollschweiler E, Baldus SE, Mueller RP, Dienes HP, Hoelscher AH, Schneider PM (2010) TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 11(1): 55-64.
48. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Borresen- Dale AL, Olopade OI, Perou CM (2012) Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 133(3): 865-880.
49. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB (2006) The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta 1759(5): 247-256.